ArticleJournal of Crohn's & colitis2014
Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease.
Article in Journal of Crohn's & colitis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Systematic review-pancreatic involvement in inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2022Pooled it
- Understanding hepatopancreatobiliary cancer risks in a population-based primary sclerosing cholangitis-inflammatory bowel disease cohort.Hepatology (Baltimore, Md.) · 2026Article
- From Isolation to Information: Launching an Online Community for Patients with Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, and Autoimmune Hepatitis in Romania-A Descriptive Study.Healthcare (Basel, Switzerland) · 2025Article
- Primary Sclerosing Cholangitis Worsens Prognosis in Patients With Inflammatory Bowel Disease: A Propensity-Matched Cohort Study.United European gastroenterology journal · 2025Article
- 20-Year Mortality in a Population-Based Cohort of Patients with Inflammatory Bowel Disease from New Zealand.Digestive diseases and sciences · 2025Article
- Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India.Intestinal research · 2023Article
- A Clinical and Pathophysiological Overview of Intestinal and Systemic Diseases Associated with Pancreatic Disorders: Causality or Casualty?Biomedicines · 2023Review
- Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.United European gastroenterology journal · 2022Article
- Associations of Inflammatory Bowel Disease and Subsequent Cancers in a Population-Based Study of Older Adults in the United States.JNCI cancer spectrum · 2022Article
- Solid extraintestinal malignancies in patients with inflammatory bowel disease.World journal of gastrointestinal oncology · 2021Review
- Increased risk of cancer in patients with primary sclerosing cholangitis.Hepatology international · 2021Article
- Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape.Current gastroenterology reports · 2021Review
- Overexpression of Cancer-Associated Stem Cell Gene OLFM4 in the Colonic Epithelium of Patients With Primary Sclerosing Cholangitis.Inflammatory bowel diseases · 2021Article
- Crohn's Disease and the Risk of Cancer.Clinics in colon and rectal surgery · 2019Review
- The Etiology of Pancreatic Manifestations in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2019Review
- Risk factors for colorectal neoplasia in patients with underlying inflammatory bowel disease: a multicenter study.Gastroenterology report · 2019Article
- Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features.Gut and liver · 2018Review
- Innate Lymphoid Cells in Intestinal Inflammation.Frontiers in immunology · 2017Review
- Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases.Journal of Crohn's & colitis · 2016Article
- Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
Abstract
introductionPrimary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) frequently co-occur. PSC is associated with increased risk for colorectal cancer (CRC). However, whether PSC is associated with increased risk of extraintestinal cancers or affects mortality in an IBD cohort has not been examined previously.
methodsIn a multi-institutional IBD cohort of IBD, we established a diagnosis of PSC using a novel algorithm incorporating narrative and codified data with high positive and negative predictive value. Our primary outcome was occurrence of extraintestinal and digestive tract cancers. Mortality was determined through monthly linkage to the social security master death index.
resultsIn our cohort of 5506 patients with CD and 5522 patients with UC, a diagnosis of PSC was established in 224 patients (2%). Patients with IBD-PSC were younger and more likely to be male compared to IBD patients without PSC; three-quarters had UC. IBD-PSC patients had significantly increased overall risk of cancers compared to patients without PSC (OR 4.36, 95% CI 2.99-6.37). Analysis of specific cancer types revealed that a statistically significant excess risk for digestive tract cancer (OR 10.40, 95% CI 6.86-15.76), pancreatic cancer (OR 11.22, 95% CI 4.11-30.62), colorectal cancer (OR 5.00, 95% CI 2.80-8.95), and cholangiocarcinoma (OR 55.31, 95% CI 22.20-137.80) but not for other solid organ or hematologic malignancies.
conclusionsPSC is associated with increased risk of colorectal and pancreatobiliary cancer but not with excess risk of other solid organ cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.